Jul 18, 2018
MINNEAPOLIS (PRWEB) JULY 17, 2018
Puma Biotechnology, Inc. and ExceleraRx® Corp. have entered into a definitive agreement whereby NERLYNX (neratinib) will be made available through Excelera to health system specialty pharmacies for the treatment of patients with early-stage, HER2-positive breast cancer. This agreement brings together one of the newest therapies for breast cancer and one of the most advanced approach to specialty pharmacy for the benefit of breast cancer patients.
The Excelera network consists of point-of-care specialty pharmacies owned by health systems and academic medical centers. Excelera offers nationally scaled infrastructure and support to help members develop best practices and gain access to limited distribution drugs and biologics and restrictive payer agreements, so they can provide continuity of care for their patients with complex and chronic conditions. The network also serves as a national platform for collaboration to optimize outpatient specialty drug therapy.
“Patients receive better care and more support through Fairview services than when we refer patients out to other specialty pharmacies. Access to NERLYNX means we will now be able to accelerate the time to therapy start, closely monitor these patients as part of our Therapy Management program and provide a seamless connection back to the provider, all within our own health system.” said Timothy Paine, Director of Industry Relations at Fairview Specialty Pharmacy. “Excelera simplified and sped up the process for accessing NERLYNX, and this partnership ensured all the requirements for safety, education, business analysis and operational logistics were all covered for the benefit of patients, providers, Puma and our specialty pharmacy.”
For health system specialty pharmacies interested in accessing NERLYNX via Excelera, email email@example.com or call 612-293-0378.
Breast Cancer Statistics
Breast cancer is the most common form of cancer in the United States. The National Cancer Institute (NCI) estimates approximately 252,710 women will be diagnosed with breast cancer this year, and approximately 15 to 20 percent of patients with breast cancer have tumors that are HER2-positive.
About NERLYNX (neratinib)
NERLYNX™ is a tyrosine kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.
Important Safety Information
There are possible side effects of NERLYNX. Patients must contact their doctor right away if they experience any of these symptoms. NERLYNX treatment may be stopped or the dose may be lowered if the patient experiences any of these side effects.
Diarrhea is a common side effect of NERLYNX. The diarrhea may be severe, and you may get dehydrated. Your healthcare provider should prescribe the medicine loperamide for you during your first 2 cycles (56 days) of NERLYNX and then as needed. To help prevent or reduce diarrhea:
Contact your healthcare provider right away if you have severe diarrhea or if you have diarrhea along with weakness, dizziness, or fever.
Changes in liver function tests are common with NERLYNX. The patient’s doctor will do tests before starting treatment, monthly during the first 3 months, and then every 3 months as needed during treatment with NERLYNX. NERLYNX treatment may be stopped or the dose may be lowered if your liver tests show severe problems. Symptoms of liver problems may include tiredness, nausea, vomiting, pain in the right upper stomach area (abdomen), fever, rash, itching, yellowing of your skin or whites of your eyes.
Patients should tell their doctor if they are planning to become pregnant, are pregnant, plan to breastfeed, or are breastfeeding. NERLYNX can harm your unborn baby. Birth control should be used while a patient is receiving NERLYNX and for at least 1 month after the last dose. If patients are exposed to NERLYNX during pregnancy, they must contact their healthcare provider right away.
Common side effects in patients treated with NERLYNX
In clinical studies, the most common side effects seen in patients taking NERLYNX were diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis (dry or inflamed mouth, or mouth sores), decreased appetite, muscle spasms, dyspepsia, changes in liver blood tests results, nail problems, dry skin, abdominal distention, weight loss, and urinary tract infection.
Patients should tell their doctor right away if they are experiencing any side effects. Report side effects to the FDA at 1-800-FDA-1088 or http://www.FDA.gov/medwatch. Patients and caregivers may also report side effects to Puma Biotechnology at 1-844-NERLYNX (1-844-637-5969).
Please see Full Prescribing Information, available at http://www.NERLYNX.com. NERLYNX is a registered trademark of Puma Biotechnology.
|Feb 14, 2019||RXinsider is Proud to Welcome our Newest Partners!|
|Feb 12, 2019||Albertsons Companies Pharmacies Adopt TemperPack's ClimaCell™ Packaging|
|Feb 07, 2019||Fagron Launches New Brand Identity and Purpose|
|Feb 07, 2019||Medicine-On-Time has come together with Clinical Support Services, a leader in M...|
|Feb 04, 2019||Letco Med and Ananda Professional Partner to Bring CBD and Education to Compound...|
|Jan 30, 2019||Texas Children’s Hospital Expands Partnership with Omnicell|
|Jan 16, 2019||Helmer Scientific Launches the First Professional Medical-grade Refrigerators|
|Jan 15, 2019||The Compliance Team™ celebrates 25 years of accreditation transformation|
|Jan 11, 2019||CORE Higher Education Group partners with Pharmacists Mutual|
|Jan 10, 2019||SCA Pharma Awarded National Outsourced I.V. Admixture Services Agreement with Pr...|
|Jan 08, 2019||Tutela Welcomes the Center for Organ Recovery and Education|
|Dec 13, 2018||PharmaLink Launches Updated Website|
|Dec 11, 2018||Jorgenson Issues Annual List of Major Challenges Facing Hospital and Health Syst...|
|Nov 29, 2018||BD Expands Integrated Medication Management to Help Tackle Hospital Drug Diversi...|
|Nov 13, 2018||Akro-Mils 2019 Catalog|
|Nov 13, 2018||New Data Shows Many Health System Pharmacies Considering Consolidated Distributi...|
|Oct 17, 2018||Retail Management Solutions Celebrates 20 Years of Pharmacy POS Innovation|
|Oct 17, 2018||Hardy Diagnostics Releases a New Locking Lid Feature for all Contact Plates|
|Oct 15, 2018||Transaction Data Systems Partners with Community Pharmacies to Fight the Opioid ...|
|Oct 12, 2018||1st Patient-Centered Respiratory Home™ Accreditation Recipient Named|
|Oct 10, 2018||Augusta University Health Selects Omnicell’s Industry-Leading Medication Manag...|
|Oct 04, 2018||QS/1® Honors Pharmacists at NCPA|
|Oct 03, 2018||Innovation to Move to New Campus in New York’s Southern Tier to Accommodate St...|
|Oct 03, 2018||Equashield and Max Care Medical to Distribute Leading Closed System Transfer Dev...|
|Oct 01, 2018||Global Needlefree Closed System Transfer Device (CSTD) Market 2018 by Manufactur...|
|Sep 23, 2018||Prudential Overall Supply Celebrates Dan Clark's 50th Employment Anniversary|
|Sep 19, 2018||RXQ Compounding Expanding in Albany|
|Sep 17, 2018||Middlesex Hospital Bolsters Pharmacy Safety and Compliance by Extending Wolters ...|
|Sep 14, 2018||Synergy Medical once again among Canada's Top 500 Companies|
|Sep 10, 2018||American Associated Pharmacies Taps FDS to Bring its Members a State-of-the-Art ...|
Connect with thousands of pharmacy professionals throughout every practice setting.